Last updated on May 2019

A Trial of Tisotumab Vedotin in Cervical Cancer

Brief description of study

A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Detailed Study Description

The purpose of the trial is to evaluate the efficacy and safety/tolerability of tisotumab vedotin in patients with previously treated, recurrent or metastatic cervical cancer. Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of tumors including cervical cancer. Preliminary safety and efficacy data observed in a cohort of previously treated cervical cancer patients suggest a positive benefit risk profile for this population of high unmet need.

Clinical Study Identifier: NCT03438396

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.